GO:0010985 negative regulation of lipoprotein particle clearance: Regulatory Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010985 describes any process that decreases the rate, frequency, or extent of lipoprotein particle clearance, the receptor-mediated removal of lipoproteins from blood and their subsequent degradation.
• PCSK9 is a central negative regulator because it binds the LDL receptor and promotes its degradation, thereby slowing LDL clearance.
• Apolipoprotein composition and charge, including apoA-I conformation and apolipoprotein F levels, modulate the efficiency of lipoprotein particle clearance.
• Hepatic proteins such as SURF4 influence plasma cholesterol by affecting lipoprotein secretion and clearance pathways.
• microRNAs can suppress the biosynthesis of triglyceride-rich lipoproteins, indirectly shaping the pool available for clearance.
• Dysregulation of this process contributes to hypertriglyceridemia, steatosis, and altered lipoprotein metabolism in chronic hepatitis C genotype 3.
Description
GO:0010985, negative regulation of lipoprotein particle clearance, is a biological process that reduces the rate, frequency, or extent of lipoprotein particle removal from the blood. Lipoprotein particle clearance itself is defined as the removal of a lipoprotein particle via receptor-mediated endocytosis followed by degradation of its constituent parts. This regulatory term is therefore concerned with the braking mechanisms that keep circulating lipoproteins, such as LDL, VLDL, and HDL, in the bloodstream for longer than they would otherwise persist. Understanding this process is important because the balance between lipoprotein production, clearance, and its negative regulation directly determines plasma lipid levels and cardiovascular risk. Mechanistically, negative regulation of lipoprotein particle clearance often converges on receptor availability. The best-characterized example is PCSK9, which binds the LDL receptor and redirects it toward degradation, thereby reducing the number of receptors available to internalize LDL particles. Beyond PCSK9, the apolipoprotein cargo itself can influence clearance efficiency: the charge and conformation of apolipoprotein A-I regulate the clearance of reconstituted high-density lipoprotein in vivo. Apolipoprotein F has also been shown to control plasma triglyceride-rich lipoprotein metabolism, providing another layer of negative regulation. For researchers, GO:0010985 provides a conceptual framework for studying how genetic, epigenetic, and post-translational mechanisms slow lipoprotein removal. This is relevant to hypertriglyceridemia, hepatic steatosis, and viral infections that reprogram lipoprotein metabolism, such as chronic hepatitis C genotype 3. Because the process is defined by its effect on clearance rate rather than by a single molecular event, it can be studied with receptor-binding assays, lipoprotein turnover studies, and CRISPR-based perturbation of candidate regulators.
negative regulation of lipoprotein particle clearance At A Glance
| GO ID | GO:0010985 |
|---|---|
| GO term | negative regulation of lipoprotein particle clearance |
| Ontology | biological_process |
| Synonym | none |
| Major function | Decreases the rate, frequency, or extent of lipoprotein particle clearance, the receptor-mediated removal of lipoproteins from blood and degradation of their components. |
| Key regulator example | PCSK9 promotes LDL receptor degradation and thereby reduces LDL clearance. |
| Lipoprotein cargo factors | Apolipoprotein A-I charge and conformation, and apolipoprotein F levels, modulate clearance efficiency. |
| Hepatic influence | Hepatic SURF4 inactivation markedly reduces plasma cholesterol, linking hepatic trafficking to lipoprotein handling. |
| Disease relevance | Hypertriglyceridemia, steatosis, and hepatitis C genotype 3-associated lipoprotein changes. |
What Is GO:0010985?
In plain terms, GO:0010985 is the set of biological events that slow down the removal of lipoprotein particles from the bloodstream. The QuickGO definition states that it is any process that decreases the rate, frequency, or extent of lipoprotein particle clearance, where lipoprotein particle clearance is the removal of a lipoprotein particle from the blood via receptor-mediated endocytosis and degradation of its constituent parts. This means the term does not describe the clearance machinery itself, but the inhibitory inputs that reduce how quickly that machinery works. Examples include PCSK9-mediated degradation of the LDL receptor, which lowers the number of receptors available for LDL uptake, and apolipoprotein-dependent changes that make a lipoprotein particle less efficiently recognized or internalized.
Why Is negative regulation of lipoprotein particle clearance Important in Cell Biology?
Negative regulation of lipoprotein particle clearance is important because it directly controls how long atherogenic and triglyceride-rich lipoproteins remain in circulation. When this braking process is excessive, LDL and triglyceride-rich particles accumulate, increasing the risk of hypertriglyceridemia, hepatic steatosis, and cardiovascular complications. Conversely, understanding the negative regulators provides therapeutic targets, as illustrated by PCSK9 inhibition, which lowers LDL by restoring LDL receptor availability and accelerating clearance. The process also intersects with viral pathogenesis, since chronic hepatitis C genotype 3 is associated with genotype-specific regulation of lipoprotein metabolism involving PCSK9 and apolipoprotein E.
• Determines plasma residence time of LDL, VLDL, and HDL particles by controlling receptor-mediated removal.
• PCSK9 is a validated drug target whose inhibition increases LDL receptor availability and lowers circulating LDL.
• Apolipoprotein A-I charge and conformation influence HDL clearance, linking particle structure to clearance rate.
• Apolipoprotein F controls plasma triglyceride-rich lipoprotein metabolism and is reduced in human steatosis.
• Hepatic SURF4 affects plasma cholesterol levels, connecting intracellular trafficking to lipoprotein clearance.
• microRNAs regulate triglyceride-rich lipoprotein biosynthesis, indirectly affecting the pool available for clearance.
• Chronic hepatitis C genotype 3 shows genotype-specific regulation of lipoprotein metabolism involving PCSK9 and apolipoprotein E.
• Genetic and bivariate analyses link obesity-related loci to serum lipid levels, highlighting polygenic control of lipoprotein traits.
• Epigenetic and transcriptomic changes, such as m6A methylation after nerve injury, illustrate broader regulatory layers that can influence metabolic gene expression.
What Happens During negative regulation of lipoprotein particle clearance?
Receptor availability is reduced
In simple terms: Fewer receptors on the cell surface means fewer doors for lipoprotein particles to enter.
The rate of lipoprotein particle clearance depends on the number of functional receptors, especially the LDL receptor, on the cell surface. PCSK9 binds the LDL receptor and promotes its degradation, which reduces receptor availability and thereby decreases the rate of LDL clearance. This is a direct mechanism of negative regulation because the lipoprotein particle itself is not altered, but the removal machinery is downregulated.
Apolipoprotein composition and charge alter recognition
In simple terms: The surface of a lipoprotein particle acts like a barcode that determines how easily it is recognized and removed.
Apolipoproteins on the particle surface influence how efficiently clearance receptors recognize and internalize the particle. The charge and conformation of apolipoprotein A-I regulate the clearance of reconstituted high-density lipoprotein in vivo, showing that structural features of the apolipoprotein cargo can slow or accelerate removal. Apolipoprotein F is also reduced in humans with steatosis and controls plasma triglyceride-rich lipoprotein metabolism, providing another apolipoprotein-dependent layer that can negatively regulate clearance.
Hepatic trafficking and secretion influence the clearance pool
In simple terms: What the liver packages and sends into the blood affects how much lipoprotein is available to be cleared.
Hepatic inactivation of murine Surf4 results in a marked reduction in plasma cholesterol, indicating that hepatic trafficking pathways can substantially alter the lipoprotein pool that is subject to clearance. Although this is not a direct receptor-blocking event, it demonstrates that negative regulation of clearance can be studied in the context of hepatic lipoprotein handling and secretion.
microRNA control of triglyceride-rich lipoprotein biosynthesis
In simple terms: Small RNA molecules can turn down the production line for triglyceride-rich lipoproteins, changing how much substrate is available for clearance.
microRNAs have been described as a novel regulatory facet for hypertriglyceridemia through their role in the regulation of triglyceride-rich lipoprotein biosynthesis. By modulating the production of these particles, microRNAs can indirectly influence the amount of lipoprotein available for clearance and thus contribute to the overall regulation of plasma lipid levels.
Viral and genotype-specific modulation of lipoprotein metabolism
In simple terms: Some viruses can reprogram how the body handles lipoproteins, and this can differ by viral genotype.
In chronic hepatitis C genotype 3, PCSK9, apolipoprotein E, and lipoviral particles show evidence for genotype-specific regulation of lipoprotein metabolism. This illustrates that negative regulation of lipoprotein particle clearance can be modulated in the context of infection, with potential consequences for lipid handling and disease progression.
Key Genes Involved in GO:0010985 negative regulation of lipoprotein particle clearance
The following genes and proteins have been experimentally linked to the regulation of lipoprotein particle clearance and related lipid metabolic processes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PCSK9 | Binds LDL receptor and promotes its degradation, reducing LDL clearance | Major therapeutic target for lowering LDL; central to negative regulation of clearance |
| APOA1 | Apolipoprotein A-I; its charge and conformation regulate HDL clearance | Structural determinant of HDL clearance efficiency |
| APOF | Apolipoprotein F; controls plasma triglyceride-rich lipoprotein metabolism | Reduced in steatosis; links apolipoprotein F to triglyceride-rich lipoprotein handling |
| SURF4 | Hepatic SURF4 inactivation reduces plasma cholesterol | Connects hepatic trafficking to plasma cholesterol and lipoprotein clearance |
| APOE | Apolipoprotein E; involved in lipoprotein metabolism and hepatitis C genotype 3 regulation | Genotype-specific regulation of lipoprotein metabolism |
| LDLR | LDL receptor; mediates LDL particle clearance and is degraded by PCSK9 | Central receptor whose availability determines clearance rate |
| MIRNA (generic) | microRNAs regulate triglyceride-rich lipoprotein biosynthesis | Novel regulatory facet for hypertriglyceridemia |
| Obesity-associated loci | Genetic association with serum lipid levels | Bivariate methods link obesity and lipid traits |
| m6A methylation machinery | Epigenetic and transcriptomic changes after nerve injury | Illustrates broader regulatory layers that can affect metabolic gene expression |
| APOB | Structural apolipoprotein of LDL and VLDL; not directly cited in the verified list but part of lipoprotein particles | Generic component of lipoprotein particles subject to clearance |
| APOC3 | Inhibits lipoprotein lipase and hepatic uptake; not directly cited in the verified list | Generic negative regulator of triglyceride-rich lipoprotein clearance |
| ANGPTL3 | Inhibits lipoprotein lipase; not directly cited in the verified list | Generic negative regulator of triglyceride-rich lipoprotein clearance |
| LPL | Lipoprotein lipase; hydrolyzes triglycerides; not directly cited in the verified list | Generic enzyme affecting lipoprotein clearance |
| IDOL | Inducible degrader of LDL receptor; not directly cited in the verified list | Generic negative regulator of LDL receptor |
| Sortilin | Sortilin; not directly cited in the verified list | Generic receptor affecting lipoprotein clearance |
| LIPC | Hepatic lipase; not directly cited in the verified list | Generic enzyme affecting HDL and remnant clearance |
| SCARB1 | Scavenger receptor class B type 1; not directly cited in the verified list | Generic HDL receptor |
| LRP1 | LDL receptor-related protein 1; not directly cited in the verified list | Generic receptor for remnant lipoprotein clearance |
How Is negative regulation of lipoprotein particle clearance Regulated?
Negative regulation of lipoprotein particle clearance is itself regulated at multiple levels. PCSK9 expression and activity are controlled transcriptionally and post-translationally, and PCSK9 binding to the LDL receptor triggers receptor degradation, which is a direct regulatory event. Apolipoprotein composition provides another regulatory layer, as the charge and conformation of apolipoprotein A-I regulate reconstituted HDL clearance in vivo. Apolipoprotein F levels are reduced in humans with steatosis and control plasma triglyceride-rich lipoprotein metabolism, indicating metabolic regulation of this apolipoprotein. microRNAs regulate triglyceride-rich lipoprotein biosynthesis, adding a post-transcriptional layer that can indirectly affect clearance. In chronic hepatitis C genotype 3, PCSK9, apolipoprotein E, and lipoviral particles show genotype-specific regulation of lipoprotein metabolism, suggesting that viral factors can modulate this process.
negative regulation of lipoprotein particle clearance and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PCSK9 | Hypercholesterolemia and cardiovascular risk via LDL receptor degradation | PCSK9 knockout or point-mutation knock-in hepatocyte cell lines |
| APOF | Hepatic steatosis and triglyceride-rich lipoprotein metabolism | APOF knockout or overexpression in hepatocytes |
| SURF4 | Plasma cholesterol regulation | SURF4 knockout in hepatic cell models |
| APOA1 | HDL clearance and cardiovascular biology | APOA1 knock-in with altered charge variants |
| APOE | Hepatitis C genotype 3 lipoprotein metabolism | APOE knockout or isoform knock-in in hepatoma cells |
Hypertriglyceridemia and steatosis
Negative regulation of lipoprotein particle clearance contributes to hypertriglyceridemia when triglyceride-rich lipoproteins are removed too slowly. microRNAs have been identified as a novel regulatory facet for hypertriglyceridemia through their role in triglyceride-rich lipoprotein biosynthesis. Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride-rich lipoprotein metabolism, linking impaired clearance regulation to fatty liver disease.
Cardiovascular risk and PCSK9
PCSK9-mediated degradation of the LDL receptor is a major mechanism that negatively regulates LDL clearance, leading to higher plasma LDL cholesterol and increased cardiovascular risk. This pathway is the basis for therapeutic strategies that inhibit PCSK9 to restore LDL receptor availability and enhance clearance.
Hepatitis C genotype 3 and lipoprotein metabolism
Chronic hepatitis C genotype 3 is associated with genotype-specific regulation of lipoprotein metabolism involving PCSK9, apolipoprotein E, and lipoviral particles. This highlights how an infectious disease can intersect with the negative regulation of lipoprotein particle clearance and alter lipid profiles.
Obesity and polygenic lipid traits
Genetic association studies using bivariate methods have explored the relationship between obesity and serum lipid levels, supporting a polygenic architecture for lipid traits that include clearance-related pathways. Epigenetic and transcriptomic analyses, such as m6A methylome studies after nerve injury, illustrate how broader regulatory layers can influence metabolic gene expression.
From negative regulation of lipoprotein particle clearance-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase lipoprotein clearance? | CRISPR knockout cell model (e.g., hepatocyte line) |
| Does a specific point mutation alter PCSK9 function? | Point-mutation knock-in via CRISPR |
| Does a disease-associated variant affect apolipoprotein function? | Knock-in of the variant allele in a hepatic cell line |
| Can a tagged protein be used to track receptor trafficking? | Tagged knock-in (e.g., GFP or HA tag) |
| Does overexpression of a microRNA reduce triglyceride-rich lipoprotein biosynthesis? | Overexpression cell model |
| Can a candidate regulator be identified from a library? | CRISPR library screening in a lipoprotein clearance reporter system |
How to Study the negative regulation of lipoprotein particle clearance Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Labeled lipoprotein uptake assay | Cellular internalization and degradation of lipoproteins | Testing whether a gene regulates clearance |
| LDL receptor degradation assay | Receptor levels after PCSK9 treatment | Studying negative regulation of LDL clearance |
| CRISPR knockout | Loss-of-function effects on clearance | Validating candidate negative regulators |
| CRISPR point-mutation knock-in | Effect of specific variants on protein function | Modeling disease-associated mutations |
| Overexpression | Gain-of-function effects on lipoprotein metabolism | Testing microRNA or gene overexpression |
| RNA-seq | Transcriptional changes in lipid metabolic genes | Identifying pathways affected by perturbation |
| m6A methylome profiling | Epigenetic modifications affecting gene expression | Linking epigenetic regulation to metabolic genes |
| Bivariate genetic analysis | Shared genetic architecture between obesity and lipid traits | Prioritizing candidate genes for functional study |
Lipoprotein clearance assays
Receptor-mediated clearance can be measured using fluorescently or radioactively labeled lipoproteins and quantifying cellular uptake or degradation. The charge and conformation of apolipoprotein A-I have been shown to regulate reconstituted HDL clearance in vivo, and similar principles apply to in vitro clearance assays. PCSK9-mediated LDL receptor degradation can be assessed by measuring receptor levels and LDL uptake.
CRISPR perturbation and screening
CRISPR knockout, point-mutation knock-in, and overexpression models allow causal testing of candidate genes in lipoprotein clearance. For example, hepatic inactivation of Surf4 in mice markedly reduced plasma cholesterol, demonstrating the power of genetic perturbation. CRISPR library screening can identify novel negative regulators of lipoprotein particle clearance in a high-throughput format.
Transcriptomic and epigenetic profiling
RNA-seq and epigenetic analyses can reveal regulatory layers that influence lipoprotein metabolism. microRNAs regulate triglyceride-rich lipoprotein biosynthesis, and their expression can be profiled by small RNA sequencing. Epigenetic combined with transcriptomic analysis, such as m6A methylome studies, provides a framework for understanding how modifications affect metabolic gene expression.
Genetic association and bioinformatics
Bivariate genetic methods can explore the relationship between obesity and serum lipid levels, helping to prioritize candidate genes for functional studies. Bioinformatics integration of GWAS, eQTL, and pathway data can nominate regulators of lipoprotein particle clearance for experimental validation.
How CRISPR Can Be Used to Study GO:0010985 negative regulation of lipoprotein particle clearance
Knockout
CRISPR knockout of candidate genes such as PCSK9, APOF, or SURF4 can test whether their loss increases or decreases lipoprotein particle clearance. Hepatic inactivation of Surf4 in mice resulted in a marked reduction in plasma cholesterol, illustrating how knockout models can reveal roles in lipoprotein handling. PCSK9 knockout would be expected to increase LDL receptor availability and enhance clearance.
Point Mutation
Point-mutation knock-in allows precise modeling of disease-associated variants in genes such as PCSK9 or APOA1. For example, mutations that alter PCSK9 binding to the LDL receptor can be introduced to study their effect on receptor degradation and clearance. Similarly, charge-altering mutations in apolipoprotein A-I can be modeled to assess effects on HDL clearance.
Knock-in
Knock-in of tagged or variant alleles enables tracking of protein localization and function. A tagged knock-in of a hepatic trafficking protein such as SURF4 could help visualize its role in lipoprotein secretion and clearance. Knock-in of apolipoprotein F variants could clarify how steatosis-associated changes affect triglyceride-rich lipoprotein metabolism.
Overexpression
Overexpression models can test gain-of-function effects, such as overexpressing a microRNA that regulates triglyceride-rich lipoprotein biosynthesis. Overexpression of PCSK9 would be expected to reduce LDL receptor levels and decrease clearance, providing a positive control for negative regulation. Overexpression of apolipoprotein F could further define its role in triglyceride-rich lipoprotein metabolism.
How EDITGENE Supports negative regulation of lipoprotein particle clearance Research
Researchers studying negative regulation of lipoprotein particle clearance-related genes often need to determine whether a candidate gene is causally involved in slowing lipoprotein removal, and CRISPR-based models provide a direct way to test this. By combining knockout, point-mutation, knock-in, and overexpression strategies, it is possible to dissect the molecular steps that control receptor availability, apolipoprotein recognition, and hepatic lipoprotein handling.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of lipoprotein particle clearance research.
Frequently Asked Questions About negative regulation of lipoprotein particle clearance
What is GO:0010985?
GO:0010985 is the Gene Ontology term for negative regulation of lipoprotein particle clearance, defined as any process that decreases the rate, frequency, or extent of lipoprotein particle clearance, the receptor-mediated removal of lipoproteins from blood and degradation of their components.
What genes are involved in negative regulation of lipoprotein particle clearance?
Key genes include PCSK9, which promotes LDL receptor degradation, APOA1, which affects HDL clearance through charge and conformation, APOF, which controls triglyceride-rich lipoprotein metabolism, and SURF4, which influences plasma cholesterol.
How does PCSK9 negatively regulate lipoprotein clearance?
PCSK9 binds the LDL receptor and promotes its degradation, reducing the number of receptors available to internalize LDL particles and thereby decreasing LDL clearance.
What is the role of apolipoprotein A-I in HDL clearance?
The charge and conformation of apolipoprotein A-I regulate the clearance of reconstituted high-density lipoprotein in vivo, meaning structural features of apoA-I can alter how quickly HDL is removed.
How is apolipoprotein F related to steatosis?
Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride-rich lipoprotein metabolism, linking it to fatty liver disease and lipoprotein handling.
Can microRNAs regulate lipoprotein clearance?
microRNAs have been described as a novel regulatory facet for hypertriglyceridemia through their role in the regulation of triglyceride-rich lipoprotein biosynthesis, which indirectly affects the pool available for clearance.
What is the connection between hepatitis C genotype 3 and lipoprotein metabolism?
Chronic hepatitis C genotype 3 shows genotype-specific regulation of lipoprotein metabolism involving PCSK9, apolipoprotein E, and lipoviral particles.
How can CRISPR be used to study lipoprotein clearance?
CRISPR knockout, point-mutation knock-in, knock-in, and overexpression models allow causal testing of candidate genes; for example, hepatic inactivation of Surf4 in mice reduced plasma cholesterol.
What methods are used to measure lipoprotein particle clearance?
Labeled lipoprotein uptake assays, LDL receptor degradation assays, and in vivo turnover studies are commonly used, and apolipoprotein A-I conformation has been shown to regulate reconstituted HDL clearance.
Why is negative regulation of lipoprotein particle clearance important for disease?
Excessive negative regulation leads to accumulation of LDL and triglyceride-rich lipoproteins, contributing to hypertriglyceridemia, steatosis, and cardiovascular risk, as illustrated by PCSK9 biology and apolipoprotein F in steatosis.
Conclusion
GO:0010985, negative regulation of lipoprotein particle clearance, captures the braking mechanisms that slow the removal of lipoproteins from circulation. PCSK9-mediated LDL receptor degradation is the best-characterized example, but apolipoprotein composition, hepatic trafficking proteins such as SURF4, and microRNA-regulated biosynthesis all contribute to this process. Dysregulation of these mechanisms is linked to hypertriglyceridemia, steatosis, and hepatitis C genotype 3-associated lipid changes. For researchers, CRISPR-based knockout, point-mutation, knock-in, and overexpression models offer a direct route to test causality and dissect the molecular steps that control lipoprotein clearance. Combining these models with clearance assays, transcriptomics, and bioinformatics will continue to reveal new regulatory nodes and therapeutic opportunities.
References
- 1. Khalifeh M et al.. 2023. A novel regulatory facet for hypertriglyceridemia: The role of microRNAs in the regulation of triglyceride-rich lipoprotein biosynthesis.. Prog Lipid Res 89:101197 PMID: 36400247
- 2. Lagace TA. 2014. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.. Curr Opin Lipidol 25(5):387-93 PMID: 25110901
- 3. Tang VT et al.. 2022. Hepatic inactivation of murine Surf4 results in marked reduction in plasma cholesterol.. Elife 11 PMID: 36193893
- 4. Braschi S et al.. 1999. Apolipoprotein A-I charge and conformation regulate the clearance of reconstituted high density lipoprotein in vivo.. J Lipid Res 40(3):522-32 PMID: 10064741
- 5. Deprince A et al.. 2023. Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride-rich lipoprotein metabolism.. Hepatology 77(4):1287-1302 PMID: 35735979
- 6. Bridge SH et al.. 2015. PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism.. J Hepatol 62(4):763-70 PMID: 25463543
- 7. Ke J et al.. 2022. Exploring the Genetic Association between Obesity and Serum Lipid Levels Using Bivariate Methods.. Twin Res Hum Genet 25(6):234-244 PMID: 36606461
- 8. Zeng F et al.. 2023. Epigenetic combined with transcriptomic analysis of the m6A methylome after spared nerve injury-induced neuropathic pain in mice.. Neural Regen Res 18(11):2545-2552 PMID: 37282488
